Inventor · disambiguated record
Celeste Richardson
Also filed as: RICHARDSON CELESTE · RICHARDSON CELESTE JEANNE
11 granted patents·12 pending applications·175 citations·filing 2015–2025
90Inventor score
Top patents by PatentIndex Score
23 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9777061B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Oct 3, 2017·85 cites·24 claims
- 0395US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0493US11666642B2PDE5 compositions and methods for immunotherapyOBSIDIAN THERAPEUTICS INC·Filed 2022·Granted Jun 6, 2023·9 cites·26 claims
- 0592US11241485B2PDE5 compositions and methods for immunotherapyOBSIDIAN THERAPEUTICS INC·Filed 2018·Granted Feb 8, 2022·11 cites·26 claims
- 0687US11058725B2CA2 compositions and methods for tunable regulationOBSIDIAN THERAPEUTICS INC·Filed 2020·Granted Jul 13, 2021·5 cites·21 claims
- 0785US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 0883US12037583B2Compositions and methods for immunooncologyNOVARTIS AG·Filed 2016·Granted Jul 16, 2024·2 cites·55 claims
- 0982US10851166B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Dec 1, 2020·1 cites·22 claims
- 1079US2025353916A1Treatment of cancer using a cd33 chimeric antigen receptorNOVARTIS AG·Filed 2025·Application pending·0 cites
- 1171US2024417722A1Compositions and methods for immunooncologyNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1270US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 1369US12338287B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Jun 24, 2025·0 cites·24 claims
- 1467US2024075064A1Compositions and methods for expansion of t cells and tumor infiltrating lymphocytesOBSIDIAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1565US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1655US2024156867A1Engineered immune cell therapeutics and methods of useCATAMARAN BIO INC·Filed 2023·Application pending·0 cites
- 1755US2022162288A1Cellular therapeutics engineered with signal modulators and methods of use thereofCATAMARAN BIO INC·Filed 2021·Application pending·0 cites
- 1852US2023051406A1Genetically modified natural killer cells and methods of use thereofCATAMARAN BIO INC·Filed 2021·Application pending·0 cites
- 1949US2022175781A1Cd40l compositions and methods for tunable regulationOBSIDIAN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2048US2021386788A1Er tunable protein regulationOBSIDIAN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2146US2023092895A1Tandem cd19 car-based compositions and methods for immunotherapyOBSIDIAN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2245US2022403001A1Pde5 derived regulatory constructs and methods of use in immunotherapyOBSIDIAN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2345US2023026259A1Ca2 compositions and methods for tunable regulationOBSIDIAN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Celeste Richardson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →